What Happens When Stomach Cancer Spreads to the Liver?

When stomach cancer spreads to the liver, the disease shifts from a localized problem to a systemic one. Liver metastases are found in roughly 5 to 14 percent of stomach cancer patients at the time of their initial diagnosis, and up to 37 percent of patients who undergo “curative” surgery for their primary tumor develop liver metastases later on.¹ The liver’s rich blood supply and its role as a filter for the portal venous system make it a frequent destination for cancer cells breaking away from a stomach tumor. Once established in the liver, these metastases change the treatment landscape, the range of symptoms, and the expected outcomes in ways that can feel overwhelming but are worth understanding clearly.

Why the Liver Is a Common Target

The stomach drains most of its blood through the portal vein directly into the liver. Cancer cells that detach from a stomach tumor ride this blood flow and encounter the liver’s vast network of tiny blood vessels, where they can lodge and begin growing. This portal-venous route is the single biggest reason the liver is such a frequent site of gastric cancer spread, and it is the same reason colorectal cancers also favor the liver as a first stop for metastasis.

Beyond the plumbing, there is a molecular side. Research has identified hundreds of genes whose activity differs between the primary stomach tumor and the liver metastases that grow from it. Some of these genes drive the “metastasis cascade,” the chain of events in which cancer cells detach, survive in the bloodstream, and take hold in a new organ.² One study comparing primary stomach tumors with their matched liver metastases found over 270 genes with altered expression, many clustered in pathways already known to promote cancer spread.³ This work is still being translated into treatments, but it helps explain why certain stomach cancers are more prone to liver spread than others.

Timing Matters: Synchronous Versus Metachronous Spread

Doctors distinguish between two scenarios. Synchronous liver metastases are already present when the stomach cancer is first diagnosed. Metachronous liver metastases show up later, sometimes months or years after the primary tumor has been surgically removed. One study tracking patients after gastric cancer surgery found that metachronous liver recurrence appeared at a median of about ten months after the initial operation.⁴

The distinction is not just academic. Synchronous metastases tend to signal more aggressive biology, because the cancer was already disseminating before treatment even began. Metachronous metastases, on the other hand, sometimes develop from microscopic tumor deposits that were invisible at the time of surgery. Both scenarios are classified as stage IV disease, but the treatment strategies and expected outcomes can differ depending on the number of liver lesions, their size, their location, and how much time has passed since the original operation.

Symptoms You Might Notice

Small liver metastases often produce no symptoms at all and are found on routine imaging during follow-up. As the tumor burden in the liver grows, a few patterns emerge. Discomfort or a dull ache in the upper right abdomen is common, sometimes accompanied by a sense of fullness or loss of appetite. Unintended weight loss, fatigue, and nausea may worsen. If metastases block bile ducts, jaundice can develop, turning the skin and eyes yellow.

Blood tests often shift as well. Liver enzymes tend to rise when metastatic deposits injure liver cells or compete with them for blood supply and oxygen.⁵ Certain patterns of liver-function abnormalities can hint at the presence of metastases even before imaging confirms them.⁶ Still, abnormal liver tests are not specific enough to confirm a diagnosis on their own, which is why imaging plays a central role.

How Liver Metastases Are Found and Assessed

CT scans are the workhorse. A systematic review of imaging for gastric cancer liver metastases found that CT detected them with moderate sensitivity and very high specificity, meaning it rarely calls something a metastasis that is not one, but it can miss smaller lesions.⁷ MRI performs comparably or slightly better for spotting small deposits because of its superior tissue contrast. PET scans, which highlight areas of high metabolic activity, have shown the highest sensitivity across gastrointestinal cancers, picking up metastases that CT and ultrasound miss.⁸

An emerging complement to imaging is liquid biopsy, which analyzes fragments of tumor DNA and circulating tumor cells in a blood draw. This approach can provide a snapshot of the tumor’s genetic makeup without a needle biopsy of the liver itself and allows clinicians to track how the cancer is changing over time or responding to treatment.⁹ Liquid biopsy is not yet standard practice for this scenario, but research is accelerating.

Treatment When Surgery Is an Option

For decades, liver metastases from stomach cancer were considered essentially inoperable. Surgeons routinely resected liver metastases from colorectal cancer with five-year survival rates around 30 to 50 percent, but gastric cancer was viewed differently because it tends to spread more diffusely.¹⁰ That view has been shifting. Carefully selected patients who undergo liver resection now achieve five-year survival rates that range from near zero to over 40 percent, depending heavily on how those patients are chosen.¹

The best surgical candidates are those with a small number of liver lesions, ideally a single metastasis, confined to one lobe, and measuring less than five centimeters. A multicenter study confirmed that patients with a solitary liver metastasis and limited lymph node involvement in the original stomach tumor fared best after hepatectomy.¹¹ A separate long-term analysis of 22 patients over 17 years reached the same conclusion: the number of liver metastases was the single strongest predictor of outcome after surgery.¹²

Current treatment strategies recommend chemotherapy before surgery to shrink the tumor and test its responsiveness, followed by an operation that aims for complete removal of both the primary stomach cancer and the liver metastasis, then additional chemotherapy afterward.¹ Some centers have also used preoperative chemotherapy with regimens combining platinum drugs and fluoropyrimidines to prepare patients for surgery.¹³

Conversion Therapy: Making the Inoperable Operable

A concept gaining traction is “conversion therapy,” in which patients initially considered too advanced for surgery receive intensive chemotherapy or other systemic treatments with the explicit goal of shrinking the disease enough to make surgery feasible. The idea is to downstage the primary tumor and control the metastases so that a surgeon can eventually perform a complete resection.¹⁴ Case reports describe patients with multiple liver metastases who, after responding well to chemotherapy, underwent successful liver resection and survived longer than expected.¹⁵ Conversion therapy is not possible for every patient. It works best when the cancer responds strongly to the initial drug regimen, and it requires close monitoring with repeat imaging to see if and when the window for surgery opens.

Targeted Drugs and Immunotherapy

Not all stomach cancers are alike at the molecular level, and the treatments available now reflect that. For tumors that overexpress a protein called HER2, trastuzumab added to first-line chemotherapy was the first targeted drug shown to improve survival in advanced gastric cancer, back in 2010. Ramucirumab, which targets the blood-vessel growth that tumors rely on, became the second targeted agent approved and was the first shown to work as a standalone therapy.¹⁶ Both drugs are now standard components of treatment in patients whose tumors qualify.

Immunotherapy, specifically checkpoint inhibitors that help the immune system recognize and attack cancer cells, has also entered the picture. Large trials showed promising results with these drugs in advanced gastric cancer, including among patients with liver metastases.¹⁷ However, the liver seems to blunt immunotherapy’s effectiveness. Patients with liver metastases consistently show lower response rates, shorter progression-free survival, and shorter overall survival compared to those whose cancer has spread elsewhere. One study found that the median time before the cancer progressed was about five months in patients with liver metastases versus about eleven months in those without.¹⁸

The liver is thought to play a role in this resistance. It is an immunologically tolerant organ by design, accustomed to filtering foreign substances from food without triggering inflammatory overreactions. That same tolerance may dampen the immune response against cancer cells growing within it, and there is evidence that liver metastases can trigger a broader suppression of the body’s antitumor immunity.¹⁹ Overcoming this immune evasion is one of the most active areas of research in the field.

Liver-Directed Procedures When Surgery Is Not Feasible

For patients whose liver metastases cannot be removed surgically, interventional radiologists offer several ways to attack the tumors directly. The most established is transarterial chemoembolization, or TACE, in which a catheter threaded into the hepatic artery delivers chemotherapy drugs directly to the tumor and then blocks the feeding blood vessel with tiny particles. A study of 56 patients with unresectable liver metastases from gastric cancer who underwent repeated TACE sessions found one-year survival around 58 percent and three-year survival around 23 percent, with a median survival of 13 months.²⁰ A more recent trial reported that TACE-based treatment outperformed standard systemic chemotherapy for postoperative liver metastases in terms of overall response.²¹

A comparison of conventional TACE with newer drug-eluting bead TACE (which slowly releases the drug from implanted beads) showed the bead approach achieved higher response rates at one month, with objective responses in about 83 percent of patients versus about 61 percent for conventional TACE.²²

Thermal ablation is another option. Microwave ablation, in which a probe inserted into the tumor generates intense heat to destroy cancer cells, has shown encouraging results. One study comparing microwave ablation plus chemotherapy to chemotherapy alone found median survival roughly doubled in the ablation group, around 25 months versus 12 months, with side effects limited mostly to temporary pain, fever, and nausea.²³ Radiofrequency ablation, which uses electrical current instead of microwaves, produces comparable survival outcomes, though a meta-analysis found that microwave ablation had a lower rate of the tumor recurring at the treatment site.²⁴

What the Prognosis Actually Looks Like

Without treatment, survival after a diagnosis of stomach cancer with liver metastases is very short. Even with systemic chemotherapy alone, one Japanese study found a five-year survival rate of only about 1.7 percent.¹⁰ The median survival across studies falls between about 7 and 14 months.¹

For the subset of patients who qualify for surgery, the numbers look meaningfully different. Some surgical series report median survival stretching well past two years, and five-year survival reaching into the 20 to 40 percent range in the most favorable cases. The key variables are the number and size of liver lesions, whether the surgery achieves complete tumor removal, how well the cancer responded to preoperative chemotherapy, and how extensive the lymph node involvement was in the original stomach tumor. Even among surgical patients, recurrence is common, which is why ongoing monitoring with CT and blood tests is part of long-term follow-up.

The Role of Early Palliative Care

Palliative care is sometimes misunderstood as a signal that treatment has ended. In advanced gastric cancer, the evidence supports introducing palliative care early and alongside active treatment, not as a replacement for it. Proactive symptom management improves quality of life, can relieve pain and nausea effectively, and in some cases helps patients stay well enough to tolerate further rounds of chemotherapy or immunotherapy.²⁵ For patients with liver metastases, this can include managing the specific complications that liver involvement brings, such as fluid accumulation in the abdomen, nutritional difficulties from impaired liver function, and the fatigue that accompanies both the disease and its treatment.

How the Liver’s Immune Environment Complicates Treatment

One of the more frustrating aspects of liver metastases is the organ’s ability to undermine treatments that work well elsewhere in the body. The liver is constantly exposed to bacterial products and food antigens arriving from the gut, and its immune environment has evolved to suppress unnecessary inflammatory reactions. Tumor cells that establish themselves there benefit from this built-in tolerance. Research has shown that liver metastases not only resist local immune attack but can dampen the immune system’s ability to fight the cancer body-wide.¹⁹ This is a problem that extends beyond stomach cancer: across multiple solid tumor types, the presence of liver metastases has been associated with worse outcomes from checkpoint-inhibitor immunotherapy.¹⁷

Some researchers are experimenting with combining liver-directed treatments like TACE or ablation with systemic immunotherapy, theorizing that destroying tumor cells locally might release antigens that “wake up” the immune system and prime it to attack surviving cancer deposits. Others are investigating ways to modify the liver’s immune microenvironment directly. None of these strategies has become standard of care yet, but the recognition that the liver actively shields metastases from the immune system has reframed how oncologists think about treating this disease.

1
PubMed Central. Strategies for Gastric Cancer With Liver Metastasis
2
PubMed Central. Molecular mechanism and potential therapeutic targets of liver metastasis from gastric cancer
3
PubMed. Identification of novel hub genes associated with liver metastasis of gastric cancer
4
PubMed. Gastric cancer with synchronous and metachronous hepatic metastasis predicted by enhancement pattern on multiphasic contrast-enhanced CT
5
PubMed Central. The predictive value of liver tests for the presence of liver metastases
6
The Journal of Laboratory and Clinical Medicine. The status of liver function in metastatic and nonmetastatic cancer
7
PubMed Central. Imaging in assessing hepatic and peritoneal metastases of gastric cancer: a systematic review
8
PubMed. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis
9
PubMed. Artificial Intelligence (AI) and Liquid Biopsy Transforming Early Detection of Liver Metastases in Gastrointestinal Cancers
10
PubMed Central. A bibliometric analysis of gastric cancer liver metastases: advances in mechanisms of occurrence and treatment options
11
PubMed. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302)
12
PubMed. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients
13
PubMed Central. Chemotherapy and resection for gastric cancer with synchronous liver metastases
14
PubMed Central. Current status and perspectives of conversion therapy for advanced gastric cancer
15
International Journal of Surgery Case Reports. Successful management of multiple liver metastasis from gastric cancer with second conversion surgery: A case report
16
PubMed Central. Targeted therapies in gastric cancer and future perspectives
17
PubMed Central. Immunotherapy in gastric cancer with liver metastasis: Challenges and opportunities
18
PubMed Central. Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis
19
PubMed Central. Gastric cancer liver metastasis will reduce the efficacy of immunotherapy
20
PubMed. Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results
21
PubMed Central. Comprehensive treatment focusing on transarterial chemoembolization for postoperative liver metastasis in gastric cancer patients
22
PubMed Central. Comparative Study of Drug-eluting Beads versus Conventional Transarterial Chemoembolization for Treating Peculiar Anatomical Sites of Gastric Cancer Liver Metastasis
23
PubMed. Microwave ablation is effective against liver metastases from gastric adenocarcinoma
24
PubMed Central. Comparative efficacy of microwave ablation and radiofrequency ablation for treating metastatic liver cancer: a systematic review and meta-analysis
25
PubMed Central. Palliative care for advanced gastric cancer